Lv2
150 积分 2022-02-28 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
20天前
已完结
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease]
28天前
已完结
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
28天前
已完结
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
1个月前
已完结
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
3个月前
已完结
Adrenal insufficiency: identification and management—summary of new NICE guidance
4个月前
已完结
Abstract CT053: Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2)
6个月前
已完结
[Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)]
8个月前
已完结
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
8个月前
已完结
A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
8个月前
已完结
皖公网安备34019202002308
